TransMedics Group, Inc.
Financials
Valuation Metrics
TransMedics Group, Inc.'s Market Cap is $2.82B. At end of 2025 it was $4.16B. Ranked #1806 of 3,112 in US market (top 58%), #650 of 1,445 on NASDAQ (top 45%), #104 of 206 in Health Care Equipment & Services (top 50%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.82B | US#1,806/3,112 Sec#104/206 |
| Revenue | $636M | US#2,224/3,112 Sec#138/206 |
| Net Income | $172M | US#1,336/3,112 Sec#64/206 |
| Total Assets | $1.43B | US#2,257/3,112 Sec#117/206 |
| Net Assets | $494M | US#2,270/3,112 Sec#117/206 |
| Employees | 898 | US#1,276/3,112 Sec#103/206 |
| Value | ||
| P/E | 16.39x | US#773/3,112 Sec#14/206 |
| P/B | 5.71x | US#2,271/3,112 Sec#149/206 |
| P/S | 4.43x | US#2,170/3,112 Sec#151/206 |
| EV/EBITDA | 23.04x | US#1,981/3,112 Sec#96/206 |
| FCF Yield | 5.37% | US#1,211/3,112 Sec#60/206 |
| Profitability | ||
| ROE | 34.80% | US#220/3,112 Sec#11/206 |
| ROA | 11.98% | US#314/3,112 Sec#19/206 |
| Op. Margin | 14.85% | US#1,240/3,112 Sec#48/206 |
| Revenue Growth | 21.18% | US#705/3,112 Sec#43/206 |
| Earnings Growth | -71.52% | US#1,964/3,112 Sec#100/206 |
| Financial Health | ||
| Debt Ratio | 190.45% | US#1,742/3,112 Sec#150/206 |
| Total Debt | $863M | US#1,556/3,112 Sec#83/206 |
| FCF | $151M | US#1,495/3,112 Sec#91/206 |
| Cash | $462M | US#1,119/3,112 Sec#66/206 |
| Current Ratio | 6.74x | US#356/3,112 Sec#23/206 |
| Net Debt/EBITDA | 2.87x | US#1,625/3,112 Sec#97/206 |
| Performance | ||
| 1Y Return | -32.35% | US#2,840/3,112 Sec#185/206 |
| 1M Return | 18.43% | US#173/3,112 Sec#22/206 |
| From 52W High | -47.72% | US#2,741/3,112 Sec#177/206 |
| 1Y MDD | -58.76% | US#2,688/3,112 Sec#170/206 |
| Trading | ||
| Volume | 1,509,584 shares | US#1,111/3,112 Sec#67/206 |
| Trading Value | $122M | US#789/3,112 Sec#62/206 |
| Per Share | ||
| EPS | $5.56 | US#585/3,112 Sec#38/206 |
| BPS | $13.83 | US#1,535/3,112 Sec#87/206 |
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.